Welcome To The Haemacure Corporation HUB On AGORACOM
A specialty bio-therapeutics company
  • Demo Video
  • Private Messages
  • Edit My Profile
  • View/Edit Portfolio

AGORACOM News Flash

AGORACOM WIRE - FRIDAY MAY 25TH, 2012

FOCUS METALS (TSXV:FMS) Changes Its Name to Focus Graphite Inc.

  • Aim to develop and manufacture the best technology graphite in the world
  • Additional shareholder value will come from investment in commercialized graphene through joint venture partner, Grafoid Inc.

Read More   |   *SPONSOR

INTERNATIONAL PBX VENTURES (TSX:PBX) Signs Copaquire Joint Venture Option Agreement - $90M Potential Payment Read More

AGORACOM Maintenance Alert: Friday Evening Downtime for About an Hour Read More

LOMIKO METALS (TSXV:LMR) Graphite and Zinc Price Outlook is Favourable Through 2013  Read More   |   *SPONSOR

 

 

Message: If you liked the quarterly... read the annual

Generic_profile
Rank: [?]
Mail Room
Points: [?]
60
Rating: [?]
Votes: 3 Score: 3.0
  • Currently 3.0/5 Stars.
Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

If you liked the quarterly... read the annual

posted on Jul 02, 08 08:15AM

If you thought the quarterly was interesting, that only tells part of the story. Read the last annual.... here's an excerpt...

Let’s review the facts:



Haemacure has an extraction and purification technology that is fully developed and offers

yield enhancements of 3 to 10 times over the traditional fractionation technology,



Haemacure has a fully developed and formulated fibrin sealant that we believe performs as

well as or better than the fibrin sealants that will be on the market when it will launch its

product towards the end of 2010,



The Swiss Red Cross licensed our extraction process in the late 1990’s, scaled it up,

conducted Phase II clinical trials and built a manufacturing facility dedicated exclusively

to our fibrin sealant – this speaks to the quality of our technology,



151 patients and subjects have received our fibrin sealant in clinical trials, without any

serious adverse events related to the product being reported – this means that our fibrin

sealant is safe, therefore meeting a first key FDA metric. In addition, these earlier trials

demonstrated that the product worked very well when compared to the standard of care,

the second key FDA metric, and



Yields are 3 to 10 times higher than industry averages. We believe that Haemacure will

# Title Rating Author / Date
2
Jul 03, 08 12:54PM

New Message

Please login to post a reply

AGORACOM Quick Tips

Bullish On China? AGORACOM Launches ChinaSecurities.com ... Check It Out
Watch
Today's Show
in 00:00:000

President's D.D.

New feature: Hub Presidents can add important links here.